Haugen B R
University of Colorado Health Sciences Center, B151, 4200 East 9th Avenue, Denver, CO 80262, USA.
Rev Endocr Metab Disord. 2000 Apr;1(3):139-45. doi: 10.1023/a:1010066728437.
Many large, retrospective studies have been performed and form the basis for how we define risk groups of patients with differentiated thyroid carcinoma and how the three basic therapeutic modalities (surgery, radioiodine and levothyroxine) affect two primary outcomes disease recurrence and death. In this review, we have hopefully distilled much of that information into a proposed current therapeutic approach to individual patients with differentiated thyroid cancer.
Zotero 插件